首页> 外文期刊>International Journal of Hematology >Novel four-way Ph translocation t(9;22;7;1)(q34;q11;q22;p13) in a chronic myeloid leukemia patient receiving tyrosine kinase inhibitor therapy
【24h】

Novel four-way Ph translocation t(9;22;7;1)(q34;q11;q22;p13) in a chronic myeloid leukemia patient receiving tyrosine kinase inhibitor therapy

机译:在接受酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者中新型四向Ph移位t(9; 22; 7; 1)(q34; q11; q22; p13)

获取原文
获取原文并翻译 | 示例
           

摘要

The occurrence of a four-way Philadelphia chromosome translocation is a very rare event in myeloid malignancies, and the phenotypic consequences of such rearrangements remain to be investigated. We describe a case of a chronic myeloid leukemia (CML) patient with a complex four-way t(9;22;7,1) translocation who received multiple tyrosine kinase inhibitor therapy. As evaluation of prognostic features in a limited number of patients with four-way Philadelphia rearrangements at present yields controversial results, our case may add further information on the prognostic impact of such abnormalities in CML patients receiving tyrosine kinase inhibitor therapy, and may help delineate a sub-group of patients requiring different therapeutic approaches.
机译:在骨髓恶性肿瘤中,四向费城染色体易位的发生是非常罕见的事件,这种重排的表型后果仍有待研究。我们描述了一个患有复杂的四向t(9; 22; 7,1)易位的慢性髓细胞性白血病(CML)患者,该患者接受了多种酪氨酸激酶抑制剂治疗。由于目前对有限数量的四向费城重排患者的预后特征进行评估产生了有争议的结果,我们的病例可能会增加此类异常对接受酪氨酸激酶抑制剂治疗的CML患者的预后影响的信息,并可能有助于确定亚组的患者需要不同的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号